BRD4 targeting nanotherapy prevents lipopolysaccharide induced acute respiratory distress syndrome
- 1 May 2021
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 601, 120536
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Protection against LPS-Induced Pulmonary Edema through the Attenuation of Protein Tyrosine Phosphatase–1B OxidationAmerican Journal of Respiratory Cell and Molecular Biology, 2012
- Emerging Role of Mast Cells and Macrophages in Cardiovascular and Metabolic DiseasesEndocrine Reviews, 2012
- Synthesis and efficient siRNA delivery of polyamine-conjugated cationic nucleoside lipidsMedChemComm, 2011
- Corticosteroids and ARDS: A review of treatment and prevention evidenceLung India, 2011
- Suppression of inflammation by a synthetic histone mimicNature, 2010
- Delivery of siRNA Therapeutics: Barriers and CarriersThe AAPS Journal, 2010
- STATs in cancer inflammation and immunity: a leading role for STAT3Nature Reviews Cancer, 2009
- Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelAMolecular and Cellular Biology, 2009
- Manipulation of inflammation in ARDS: achievable goal or distant target?Thorax, 2006
- Reactive nitrogen species in the respiratory tractEuropean Journal of Pharmacology, 2006